Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and delivering novel therapies for central nervous system (CNS) disorders where treatment options are limited. The company's mission is to transform the approach to treating CNS conditions by accelerating the invention and adoption of life-changing medicines that meaningfully improve the lives of patients. Headquartered in New York, NY, at One World Trade Center, Axsome focuses on addressing unmet medical needs in neurology and psychiatry.

Axsome's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), approved for major depressive disorder (MDD) and recently for agitation associated with Alzheimer's disease (ADA). Another key product is Sunosi (solriamfetol), used to treat excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The company also has SYMBRAVO, approved for the acute treatment of migraine. Its robust pipeline features candidates like AXS-12 for narcolepsy and AXS-14 for fibromyalgia, alongside further development of solriamfetol for conditions such as ADHD and major depressive disorder with excessive daytime sleepiness.

In a significant development, Axsome Therapeutics received FDA approval for Auvelity (AXS-05) for agitation associated with Alzheimer's disease on April 30, 2026, marking a substantial market opportunity. The commercial launch for this indication is anticipated in June 2026. Led by CEO and Chairman Dr. Herriot Tabuteau, the company has demonstrated strong revenue growth from its existing products, Auvelity and Sunosi, and is strategically positioned for further expansion within the neuroscience sector with a late-stage pipeline targeting numerous unmet medical needs.